
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE				
	32,877 erial No. ↑	ATTENTION:	Office of Initial Patent Ex Customer Service Center	
		2002	F	
Filed: Sep 18, 2000 Title: PHARMACEUTICAL COMPOS PREPARATION THEREOF	SITION HAVING ANTI	TUMOR ACTIVIT	Y AND PROCESS FOR TH	
		Date: January 2	28, 2002	
Asr Commissioner of Patents Washington, D.C. 202031			28, 2002 ECEIPT	EN 1600/0
Sir: RI	EQUEST FOR CORRE	CTED FILING RE	ECEIPT &	
Attached is a copy of the official corrected filing receipt is respect		PTO in the above		-
2. There is an error with respect to	the following data which	ch is		
incorrectly enter			omitted Correct data	
→ 1.		1.		
2. Applicant's Addres	ss	2.		
3. Title		3.		
4. Filing Date		4.		
5. Serial Number		5.		
6. 🔀 Foreign/PCT Appl	ication Re		8/47025 11/03/1998 8/48277 11/11/1998	
7. Other		7.	0/402// 11/11/1990	
3. It is understood that the PTO no	longer charges for cor	recting filing recei	pts even when the error is a	applicants'
mistake, but if that is incorrect at 3975 under Order No. 71404/27		correction please	charge our Deposit Accoun	t No. 03-
	Pillsbury Winthrop L Intellectual Property			
1600 Tysons Boulevard	By Atty: Glenn J. P	erry	Reg. No.	28458
McLean, VA 22102 Tel: (703) 905-2000	d			
Atty/Sec: gjp/mll	Sig:	- 1	Fax: (703) 90 Tel: (703) 9 0	

(Attach Filing Receipt copy and PTO receipt PAT-103A)



TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

FIL FEE REC'D ATTY.DOCKET.NO **DRAWINGS** TOT CLAIMS IND CLAIMS GRP ART UNIT APPLICATION NUMBER FILING DATE PM271427 12 4 1651 719 09/582.877 09/18/2000

CONFIRMATION NO. 3124

FILING RECEIPT

OC000000007098841

PILLSBURY WINTHROP

NOV 2 8 2001

Pillsbury Madison & Sutro Ninth Floor East Tower 1100 New York Avenue NW Washington, DC 20005-3918

Date Mailed: 11/20/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, MAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Song-Bae Kim, Chungcheongnam-do, KOREA, REPUBLIC OF;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/KR99/00659 11/03/1999

Foreign Applications

AUSTRIA 1998/47025 11/03/1998 AUSTRIA 1998/48277 11/11/1998

If Required, Foreign Filing License Granted 11/20/2001

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Pharmaceutical composition having antitumor activity and process for the preparation thereof



LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).